$LLY News

Eli Lilly (NYSE:LLY) Shows Strong Growth and a Compelling Technical Setup

Amplitude Therapeutics Partners With Eli Lilly Over Discovery, Development Of taRNA Vaccine Candidates For Infectious Diseases

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

Eli Lilly Canada Says Continues To Take Action To Address Promotion And Sale Of Unapproved And Illegal Retatrutide Products In Canada; Disagrees With Characterizations In Canada Revenue Agency’s Application; Will Respond Formally Through Court Process In Due Course

5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call

Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Lilly gains access to market that could add millions of customers

CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits

Eli Lilly (LLY) Q2 2026 Earnings Call Transcript

Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Lilly Targets Black-Market Retatrutide Sellers

IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point

Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup